Shares of 4basebio PLC (LON:4BB - Get Free Report) traded down 2% on Wednesday . The company traded as low as GBX 1,200 ($15.21) and last traded at GBX 1,200 ($15.21). 3,555 shares traded hands during trading, a decline of 19% from the average session volume of 4,376 shares. The stock had previously closed at GBX 1,225 ($15.53).
4basebio Price Performance
The stock has a market cap of £151.80 million, a P/E ratio of -1,506.41 and a beta of 1.09. The company has a debt-to-equity ratio of 201.47, a quick ratio of 3.52 and a current ratio of 2.73. The firm has a 50-day moving average price of GBX 1,297.77 and a 200-day moving average price of GBX 1,410.40.
Insiders Place Their Bets
In other 4basebio news, insider Heikki Lanckriet acquired 46,500 shares of the company's stock in a transaction that occurred on Friday, November 15th. The shares were acquired at an average price of GBX 1,325 ($16.80) per share, with a total value of £616,125 ($780,992.52). 68.44% of the stock is owned by corporate insiders.
4basebio Company Profile
(
Get Free Report)
4basebio PLC engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company offers AVV and Lentivirus manufacturing services for use in gene therapies and vaccines.
Further Reading
Before you consider 4basebio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4basebio wasn't on the list.
While 4basebio currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
